Important Safety Information for BOOSTRIX

• Severe allergic reaction after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine, or to any component of BOOSTRIX, or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine is a contraindication
• Prior to administration, review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions to assess benefits and risk. Epinephrine and other appropriate agents used for control of immediate allergic reactions must be immediately available should an acute anaphylactic reaction occur
• The tip caps of the prefilled syringes for BOOSTRIX contain natural rubber latex, which may cause allergic reactions
• The decision to give BOOSTRIX should be based on benefits and risks if Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior tetanus toxoid-containing vaccine
• Progressive or unstable neurologic conditions are reasons to defer vaccination with a pertussis-containing vaccine, including BOOSTRIX
• Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of tetanus toxoid-containing vaccine should not receive BOOSTRIX unless 10 years have elapsed since the last dose of a tetanus toxoid-containing vaccine
• Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
• In clinical studies, common adverse reactions were pain, redness, and swelling at the injection site, increase in arm circumference of injected arm, headache, fatigue, gastrointestinal symptoms, and fever
• Vaccination with BOOSTRIX may not result in protection in all vaccine recipients

Please see full Prescribing Information for BOOSTRIX.